Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis

Ginzler, Ellen M.; Dooley, Mary Anne; Aranow, Cynthia; Kim, Mimi; Buyon, Jill P.; Merrill, Joan T.; Petri, Michelle; Gilkeson, Gary S.; Wallace, Daniel J.; Weisman, Michael H.; Appel, Gerald B.

doi:10.1056/nejmoa043731

articleNew England Journal of MedicineNov 23, 2005BRONZE OA

Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis

EMEllen M. Ginzler MAMary Anne Dooley CACynthia Aranow MKMimi Kim JPJill P. Buyon

State University of New York · SUNY Downstate Health Sciences University · +7 more institutions

Indexed incrossref

Abstract

In this 24-week trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile.

Citation impact

1,124

total citations

FWCI: 42.48
Percentile: 100%
References: 34

Citations per year

Authors

EM
Ellen M. GinzlerCorresponding
State University of New York, SUNY Downstate Health Sciences University
MA
Mary Anne Dooley
University of North Carolina at Chapel Hill
CA
Cynthia Aranow
State University of New York, SUNY Downstate Health Sciences University
MK
Mimi Kim
JP
Jill P. Buyon
New York University Langone Orthopedic Hospital

Topics & keywords

Topics

Systemic Lupus Erythematosus Research100%
Liver Diseases and Immunity100%
Inflammatory Bowel Disease100%

Keywords

Medicine
Cyclophosphamide
Lupus nephritis
Mycophenolate
Regimen
Internal medicine
Clinical endpoint
Surgery

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.